Fishing, Photography&Solving Cancer. Same Same but Different
Oncology Venture’s CTO, Thomas Jensen has been chosen to speak at TEDxBozeman 2016 that will be held on Saturday April 9th, 2016 in Bozeman, Montana USA. The title of the talk is: “Fly fishing, Photography & Solving Cancer…Same Same but Different!” He will speak about the remarkable parallels between the art and science of: fly fishing, photography and solving cancer with our Drug Response Predictor- DRP®.
The Drug Response Predictor platform used in Oncology Venture was invented in 2004 at Medical Prognosis Institute –MPI. It is a science and technology platform where data from cell line assays are translated into relevant information for the treatment of cancer patients. The Drug Response Predictor platform – DRP® is today used by Oncology Venture for changing the odds of anti-cancer drugs under development where patients are screened for likelihood of sensitivity before treated with the drug under development. The DRP® is used by MPI for development of personalized medicine for cancer patients.
Thomas serves as CTO at Oncology Venture and Medical Prognosis Institute. He is pioneering the bridging of good science, effective laboratory techniques, and bioinformatics to advance the biology of cancer. He founded and leads the Medical Prognosis Institute’s –MPI laboratories in Denmark and in the USA. Amongst Thomas' accolades are his inventions of molecular biological guidelines and techniques for high-quality RNA processing. This allows for high-resolution analysis of cancer patients' biopsies. His inventions are an important foundation of MPI's Drug Response Predictor platform – a high-resolution bioinformatics tool that predicts the sensitivity and resistance of anticancer drugs.
Bozeman, Montana is Thomas’ sanctuary where he enters his mental laboratory to hear himself think, and concoct big ideas to help solve one of the 21st century's biggest problem -cancer.
He basks in Bozeman's natural serenity equipped with fly rods and cameras, same same but different from his daily work tool at the lab. Montana is where he has discovered the remarkable parallels between the art and science of: fly fishing, photography and cancer solving.
What is TEDx?
In the spirit of ideas worth spreading, TED has created a program called TEDx. TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. Our event is called TEDxBozeman, where x = independently organized TED event. At our TEDxBozeman event, TEDTalks video and live speakers will combine to spark deep discussion and connection in a small group.
If you are in the Bozeman neck of the woods on April 9th, come see Thomas Jensen along with a roster of interesting speakers inspire the TEDxBozeman 2016 theme of “Confluence.”
http://www.tedxbozeman.com/speakers/
For more information, please contact:
Peter Buhl Jensen, CEO
Phone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com
http://www.oncologyventure.com/
About Oncology Venture Sweden AB
Oncology Venture improves the odds compared to traditional drug development. Instead of treating all patents with the same cancer disease patients will be screened beforehand and only patients who have a likelihood of responding to the anti-cancer drug will then be treated. Having a better defined patient population risk, cost will be reduced, and the development process will be more efficient and the cancer product and OV’s Companion Diagnostic can lead to clinical and commercial success. OV aims to sell the combined solution after proof-of-concept. Our current portfolio of drugs: Irofulven – developed from a natural fungus (for prostate cancer where it worked in 10% of unselected patients) and APO010 – a T-Cell mimic Immuno-Oncology product (for Multiple Myeloma – a blood cancer and Breast cancer). Oncology Venture has license to use Drug Response Prediction – DRPTM – to significantly increase the likelihood of success in clinical trials. Oncology Venture aims to rescue cancer drugs, which has shown excellent anticancer activity but in too few of the treated patients to obtain approval. DRPTM has demonstrated statistically significant prediction of clinical trial results in 26 out of 32 tested clinical studies. Oncology Venture Sweden AB runs cancer drug development through the fully owned Danish daughter company Oncology Venture ApS.